Robert Davis, Merck CEO

Covid-19 roundup: Mod­er­na's stock plunges af­ter low­er sales fore­cast is re­vealed; Re­gen­eron sees $804M in Q3 mon­o­clon­al an­ti­body sales

Mod­er­na’s stock $MR­NA plunged more than 14% in pre­mar­ket trad­ing on Thurs­day af­ter the biotech cut its end-of-year vac­cine sales fore­cast.

Ac­cord­ing to its Q3 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.